Join us on Thursday, March 30th at 9am EST (10amAST) to learn about using the Canadian Partnership for Tomorrow’s Health to identify the earliest determinants of disease evolution and aging. Registration details: https://ihccglobal.org/ihcc-educational-webinar-series/.
Properly consented population cohorts are incredibly valuable for studying the factors associated with aging and disease before the first diseases are diagnosed. In the Canadian Partnership for Tomorrows Health (CanPath) we have recruited over 350,000 participants who have consented to provide biologics, physical measures and health information longitudinally, while also consenting to follow-ups through health records over the next 30-50 years. Our studies genomic and molecular phenotyping studies have identified a number of critical factors associated with the development of cancers pre-diagnosis. Utilizing single-cell approaches we have identified alternative factors associated with healthy blood aging. Together, CanPath demonstrates the power of population cohorts to support early disease and prevention studies that are impacting health policy.
Dr. Philip Awadalla is the National Scientific Director of the Canadian Partnership for Tomorrows Health (CanPath) and is the Executive Director of the Ontario Health Study (OHS). He is a Professor the Department of Molecular Genetics, and School of Public Health, at the University of Toronto. He is the Director of Computational Biology at the Ontario Institute of Cancer Research where he leads a research program studying the genomic and environmental determinants of early cancer evolution, aging, and studies fundamental processes shaping genomic variation. He is on the Steering Committee of International Hundred Thousand + Cohort Consortium.